Zobrazeno 1 - 10
of 205
pro vyhledávání: '"Rodabe N. Amaria"'
Autor:
Elizabeth M. Burton, Rodabe N. Amaria, Tina Cascone, Myriam Chalabi, Neil D. Gross, Elizabeth A. Mittendorf, Richard A. Scolyer, Padmanee Sharma, Paolo A. Ascierto
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic
Externí odkaz:
https://doaj.org/article/cfb90c8c178541e79522621d06de02ab
Autor:
Joel Ho, Jane Mattei, Michael Tetzlaff, Michelle D. Williams, Michael A. Davies, Adi Diab, Isabella C. Glitza Oliva, Jennifer McQuade, Sapna P. Patel, Hussein Tawbi, Michael K. Wong, Sarah B. Fisher, Ehab Hanna, Emily Z. Keung, Merrick Ross, Roi Weiser, Shirley Y. Su, Michael Frumovitz, Larissa A. Meyer, Amir Jazaeri, Curtis A. Pettaway, B. Ashleigh Guadagnolo, Andrew J. Bishop, Devarati Mitra, Ahsan Farooqi, Roland Bassett, Silvana Faria, Priyadharsini Nagarajan, Rodabe N. Amaria
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundNeoadjuvant checkpoint inhibition (CPI) has recently demonstrated impressive outcomes in patients with stage 3 cutaneous melanoma. However, the safety, efficacy, and outcome of neoadjuvant CPI in patients with mucosal melanoma (MM) are not
Externí odkaz:
https://doaj.org/article/130631cb682140daaa725bf5649ba720
Autor:
Dai Ogata, Lauren E. Haydu, Isabella C. Glitza, Sapna P. Patel, Hussein A. Tawbi, Jennifer L. McQuade, Adi Diab, Suhendan Ekmekcioglu, Michael K. Wong, Michael A. Davies, Rodabe N. Amaria
Publikováno v:
Cancer Medicine, Vol 10, Iss 7, Pp 2293-2299 (2021)
Abstract Background Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. However, the understanding of the efficacy of anti‐PD‐1 for acral melanoma (AM) and mucosal melanoma (MM) is
Externí odkaz:
https://doaj.org/article/978825aa55664d048e71fed80d5c0d69
Autor:
Taylor C. Duke, MD, Ranjit Nair, MD, Carlos Torres-Cabala, MD, Rodabe N. Amaria, MD, Elizabeth Keiser, MD, Roberto Miranda, MD, Swaminathan P. Iyer, MD, Meghan Heberton, MD
Publikováno v:
JAAD Case Reports, Vol 6, Iss 12, Pp 1264-1267 (2020)
Externí odkaz:
https://doaj.org/article/ad82ea49a92c40879ff2c5dc18cfbd1b
Autor:
Sapna Patel, Adi Diab, Michael A. Davies, Jennifer L. McQuade, Michael K. Wong, Isabella C. Glitza, Hussein A. Tawbi, Rodabe N. Amaria, Chantal Saberian, Enrique Alvarez, Amer M. Najjar, Laszlo G. Radvanyi, Cara L. Haymaker, Roland L. Bassett, Silvana C. Faria, Sapna Parshottam, Victor Prieto, Elizabeth J. Shpall
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) are believed to optimally activate antigen-specific T lymphocytes.
Externí odkaz:
https://doaj.org/article/2177a92454d247c7ae2a0821d3eb7f58
Autor:
Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab, Gregg A. Staerkel, Priyadharsini Nagarajan, Carlos A. Torres-Cabala, Beth A. Chasen, Jennifer A. Wargo, Victor G. Prieto, Rodabe N. Amaria, Jonathan L. Curry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Abstract Background Immune checkpoint therapy has dramatically changed the landscape of cancer therapy, providing an efficacious and durable therapeutic option for patients with advanced-stage disease. However, dermatologic toxicities are a well-reco
Externí odkaz:
https://doaj.org/article/702c89c0e6e04f88a481332e31c49761
Autor:
Robert A. Szczepaniak Sloane, Michael G. White, Russell G. Witt, Anik Banerjee, Michael A. Davies, Guangchun Han, Elizabeth Burton, Nadim Ajami, Julie M. Simon, Chantale Bernatchez, Lauren E. Haydu, Hussein A. Tawbi, Jeffrey E. Gershenwald, Emily Keung, Merrick Ross, Jennifer McQuade, Rodabe N. Amaria, Khalida Wani, Alexander J. Lazar, Scott E. Woodman, Linghua Wang, Miles C. Andrews, Jennifer A. Wargo
Publikováno v:
Cancers, Vol 13, Iss 21, p 5301 (2021)
Metastatic melanoma is a deadly malignancy with poor outcomes historically. Immuno-oncology (IO) agents, targeting immune checkpoint molecules such as cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1), have revol
Externí odkaz:
https://doaj.org/article/c8064d6d4da44883816ebcc8ea0a1965
Autor:
Alexandre Reuben, Christine N. Spencer, Peter A. Prieto, Vancheswaran Gopalakrishnan, Sangeetha M. Reddy, John P. Miller, Xizeng Mao, Mariana Petaccia De Macedo, Jiong Chen, Xingzhi Song, Hong Jiang, Pei-Ling Chen, Hannah C. Beird, Haven R. Garber, Whijae Roh, Khalida Wani, Eveline Chen, Cara Haymaker, Marie-Andrée Forget, Latasha D. Little, Curtis Gumbs, Rebecca L. Thornton, Courtney W. Hudgens, Wei-Shen Chen, Jacob Austin-Breneman, Robert Szczepaniak Sloane, Luigi Nezi, Alexandria P. Cogdill, Chantale Bernatchez, Jason Roszik, Patrick Hwu, Scott E. Woodman, Lynda Chin, Hussein Tawbi, Michael A. Davies, Jeffrey E. Gershenwald, Rodabe N. Amaria, Isabella C. Glitza, Adi Diab, Sapna P. Patel, Jianhua Hu, Jeffrey E. Lee, Elizabeth A. Grimm, Michael T. Tetzlaff, Alexander J. Lazar, Ignacio I. Wistuba, Karen Clise-Dwyer, Brett W. Carter, Jianhua Zhang, P. Andrew Futreal, Padmanee Sharma, James P. Allison, Zachary A. Cooper, Jennifer A. Wargo
Publikováno v:
npj Genomic Medicine, Vol 2, Iss 1, Pp 1-11 (2017)
Melanoma: Tumor differences within a patient may explain heterogeneous responses Patients with metastatic melanoma display molecular and immune differences across tumor sites associated with differential drug responses. A team led by Jennifer Wargo f
Externí odkaz:
https://doaj.org/article/95f4f8da81aa4220b7ea3fea4b7af4b6
Autor:
Meredith S. Pelster, Rodabe N. Amaria
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
The development of BRAF and MEK inhibitors (BRAFis and MEKis) and immune checkpoint inhibitors have changed the management of advanced stage melanoma and improved the outcomes of patients with this malignancy. However, both therapeutic approaches hav
Externí odkaz:
https://doaj.org/article/430d96a1f13248108d44522415723e00
Autor:
Marie-Andrée Forget, René J. Tavera, Cara Haymaker, Renjith Ramachandran, Shuti Malu, Minying Zhang, Seth Wardell, Orenthial J. Fulbright, Chistopher Leroy Toth, Audrey M. Gonzalez, Shawne T. Thorsen, Esteban Flores, Arely Wahl, Weiyi Peng, Rodabe N. Amaria, Patrick Hwu, Chantale Bernatchez
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Following the clinical success achieved with the first generation of adoptive cell therapy (ACT) utilizing in vitro expanded tumor-infiltrating lymphocytes (TILs), the second and third generations of TIL ACT are evolving toward the use of genetically
Externí odkaz:
https://doaj.org/article/32c88309dbec4abdb3ae43906c3e7255